晚期三阴性乳腺癌-话题@MedSci

#晚期三阴性乳腺癌#

5篇内容 | 719人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1927278, encodeId=eab3192e27821, content=<a href='/topic/show?id=74f0598066f' target=_blank style='color:#2F92EE;'>#晚期三阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌, objectType=article, longId=301566, objectId=a12430156640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a12430156640, replyNumber=0, likeNumber=51, createdTime=2022-09-14, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a12430156640, moduleTitle=Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a12430156640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1927277, encodeId=8212192e27775, content=<a href='/topic/show?id=74f0598066f' target=_blank style='color:#2F92EE;'>#晚期三阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌, objectType=article, longId=221752, objectId=5171221e521f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5171221e521f, replyNumber=0, likeNumber=53, createdTime=2022-10-15, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5171221e521f, moduleTitle=Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5171221e521f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1927276, encodeId=3d3c192e27628, content=<a href='/topic/show?id=74f0598066f' target=_blank style='color:#2F92EE;'>#晚期三阴性乳腺癌#</a>, objectTitle=AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％, objectType=article, longId=163455, objectId=500616345538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500616345538, replyNumber=0, likeNumber=39, createdTime=2019-10-26, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500616345538, moduleTitle=AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500616345538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1927274, encodeId=c8c5192e27468, content=<a href='/topic/show?id=74f0598066f' target=_blank style='color:#2F92EE;'>#晚期三阴性乳腺癌#</a>, objectTitle=袁芃教授：晚期三阴性乳腺癌内科治疗进展（一）, objectType=article, longId=136750, objectId=dacf136e50e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dacf136e50e9, replyNumber=0, likeNumber=46, createdTime=2018-04-28, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dacf136e50e9, moduleTitle=袁芃教授：晚期三阴性乳腺癌内科治疗进展（一）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dacf136e50e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1927275, encodeId=ca5e192e27575, content=<a href='/topic/show?id=74f0598066f' target=_blank style='color:#2F92EE;'>#晚期三阴性乳腺癌#</a>, objectTitle=袁芃教授：晚期三阴性乳腺癌内科治疗进展（二）, objectType=article, longId=137223, objectId=768b13e22365, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=768b13e22365, replyNumber=0, likeNumber=49, createdTime=2019-03-25, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=768b13e22365, moduleTitle=袁芃教授：晚期三阴性乳腺癌内科治疗进展（二）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=768b13e22365)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期三阴性乳腺癌

2020-05-29

yankaienglish (审核中...)

前往app查看评论内容

#晚期三阴性乳腺癌#

Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌

2022-09-14

yankaienglish (审核中...)

前往app查看评论内容

#晚期三阴性乳腺癌#

Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌

2022-10-15

yankaienglish (审核中...)

前往app查看评论内容

#晚期三阴性乳腺癌#

AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％

2019-10-26

yankaienglish (审核中...)

前往app查看评论内容

#晚期三阴性乳腺癌#

袁芃教授：晚期三阴性乳腺癌内科治疗进展（一）

2018-04-28

yankaienglish (审核中...)

前往app查看评论内容

#晚期三阴性乳腺癌#

袁芃教授：晚期三阴性乳腺癌内科治疗进展（二）

2019-03-25

科室
- - 订阅+
  - 更多科室
工具
服务